Automated Analysis of Drawing Process to Estimate Global Cognition in Older Adults: Preliminary International Validation on the US and Japan Data Sets

Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer's Disease

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease with cognitive decline and behavioral dysfunction. AD will become a global public health concern due to its increasing prevalence brought on by the severity of global aging. It is critical to understand the pathogenic mechanisms of AD and investigate or pursue a viable therapy strategy in clinic. Amyloid-β (Aβ) accumulation and abnormally hyperphosphorylated tau protein are the main regulating variables in the pathological phase of AD. And neuroinflammation brought on by activated microglia was found to be one risk factor contributing to changes in Aβ and tau pathology. It is important to investigate the unique biomarkers of early diagnosis and advanced stage, which may help to elucidate the specific pathological process of AD and provide potential novel therapeutic targets or preventative measures.

A tablet-based multi-dimensional drawing system can effectively distinguish patients with amnestic MCI from healthy individuals

The population with dementia is expected to rise to 152 million in 2050 due to the aging population worldwide. Therefore, it is significant to identify and intervene in the early stage of dementia. The Rey-Osterreth complex figure (ROCF) test is a visuospatial test scale. Its scoring methods are numerous, time-consuming, and inconsistent, which is unsuitable for wide application as required by the high number of people at risk. Therefore, there is an urgent need for a rapid, objective, and sensitive digital scoring method to detect cognitive dysfunction in the early stage accurately. This study aims to clarify the organizational strategy of aMCI patients to draw complex figures through a multi-dimensional digital evaluation system. At the same time, a rapid, objective, and sensitive digital scoring method is established to replace traditional scoring. The data of 64 subjects (38 aMCI patients and 26 NC individuals) were analyzed in this study. All subjects completed the tablet's Geriatric Complex Figure (GCF) test, including copying, 3-min recall, and 20-min delayed recall, and also underwent a standardized neuropsychological test battery and classic ROCF test. Digital GCF (dGCF) variables and conventional GCF (cGCF) scores were input into the forward stepwise logistic regression model to construct classification models. Finally, ROC curves were made to visualize the difference in the diagnostic value of dGCF variables vs. cGCF scores in categorizing the diagnostic groups. In 20-min delayed recall, aMCI patients' time in air and pause time were longer than NC individuals. Patients with aMCI had more short strokes and poorer ability of detail integration (all p < 0.05). The diagnostic sensitivity of dGCF variables for aMCI patients was 89.47%, slightly higher than cGCF scores (sensitivity: 84.21%). The diagnostic accuracy of both was comparable (dGCF: 70.3%; cGCF: 73.4%). Moreover, combining dGCF variables and cGCF scores could significantly improve the diagnostic accuracy and specificity (accuracy: 78.1%, specificity: 84.62%). At the same time, we construct the regression equations of the two models. Our study shows that dGCF equipment can quantitatively evaluate drawing performance, and its performance is comparable to the time-consuming cGCF score. The regression equation of the model we constructed can well identify patients with aMCI in clinical application. We believe this new technique can be a highly effective screening tool for patients with MCI.

Quantification of Movement Error from Spiral Drawing Test

Parkinson's disease is a neurodegenerative disease that often comes with symptoms such as muscle stiffness, slowness of movement, and tremors at rest. Since this disease negatively influences the quality of life in patients, an early and accurate diagnosis is important for slowing the progression of the disease and providing effective treatment to patients. One of the quick and easy methods for diagnosing is the spiral drawing test and the differences between the target spiral picture and the drawing by patients can be used as an indicator of movement error. Simply, the average distance between paired samples of the target spiral and the drawing can be easily calculated and used as the level of movement error. However, finding the correct pair of samples between the target spiral and the drawing is relatively difficult, and the accurate algorithm to quantify the movement error has not been thoroughly studied. In this study, we propose algorithms applicable to the spiral drawing test, that ultimately can be used to measure the level of movement error in Parkinson's disease patients. They are equivalent inter-point distance (ED), shortest distance (SD), varying inter-point distance (VD), and equivalent angle (EA). To evaluate the performance and sensitivity of the methods, we collected data from simulation and experiments with healthy subjects and evaluated the four methods. As a result, in normal (good drawing) and severe symptom (poor drawing) conditions, the calculated errors were 3.67/5.48 from ED, 0.11/1.21 from SD, 0.38/1.46 from VD and 0.01/0.02 from EA, meaning that ED, SD, and VD measure movement error with high noise while EA is sensitive to even small symptom levels. Similarly, in the experiment data, only EA shows the linear increase of error distance to changing symptom levels from 1 to 3. In summary, we found that EA is the most effective algorithm in finding the correct pair of samples between the spiral and the drawing, and consequently yields low errors and high sensitivity to symptom levels.

Characteristics of Drawing Process Differentiate Alzheimer’s Disease and Dementia with Lewy Bodies

Background: Early differential diagnosis of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) is important for treatment and disease management, but it remains challenging. Although computer-based drawing analysis may help differentiate AD and DLB, it has not been extensively studied. Objective: We aimed to identify the differences in features characterizing the drawing process between AD, DLB, and cognitively normal (CN) individuals, and to evaluate the validity of using these features to identify and differentiate AD and DLB. Methods: We collected drawing data with a digitizing tablet and pen from 123 community-dwelling older adults in three clinical diagnostic groups of mild cognitive impairment or dementia due to AD (n = 47) or Lewy body disease (LBD; n = 27), and CN (n = 49), matched for their age, sex, and years of education. We then investigated drawing features in terms of the drawing speed, pressure, and pauses. Results: Reduced speed and reduced smoothness in speed and pressure were observed particularly in the LBD group, while increased pauses and total durations were observed in both the AD and LBD groups. Machine-learning models using these features achieved an area under the receiver operating characteristic curve (AUC) of 0.80 for AD versus CN, 0.88 for LBD versus CN, and 0.77 for AD versus LBD. Conclusion: Our results indicate how different types of drawing features were particularly discriminative between the diagnostic groups, and how the combination of these features can facilitate the identification and differentiation of AD and DLB.